



Follow-Up Care for Children Prescribed ADHD Medication (ADD-E)

HEDIS® Measurement Year 2024

Measure description: The percentage of children ages 6-12 who are newly prescribed attention-deficit/hyperactivity disorder ADHD medication who had at least three follow-up care visits within a 10-month period, one of which was within 30 days of when the first ADHD medication was dispensed. Two rates are reported:

Initiation Phase

- One follow-up visit with a provider with prescribing authority within 30 days of the first prescription

Continuation and Maintenance Phase

- Two or more follow-up visits with a provider within 270 days (nine months) after the initiation phase
- Member remains on the ADHD medication for at least 210 days

ADHD medication

- Atomoxetine
- Clonidine
- Dexamethylphenidate
- Dextroamphetamine
- Guanfacine
- Lisdexamfetamine
- Methamphetamine
- Methylphenidate

Strategies for improvement

- If you prescribe a medication used for ADHD, consider limiting the first prescription to a 30-day supply.
- Educate the parent or guardian that the child must be seen within 30 days of starting the medication to evaluate if the medication is working as expected and assess any adverse effects.
- Verify the parent or guardian understands the requirement above and keeps the appointment for refill prescriptions.
- Discuss the importance of follow-up appointments with the parent/guardian and ensure that the child has at least two additional follow-up appointments with a medical provider or a behavioral health provider in the 9 months after the initial 30-day visit.